Castle Biosciences (CSTL) on Sunday reported data from studies backing the "clinical utility" of its DecisionDx-Melanoma and DecisionDx-SCC tests in guiding treatment paths in patients with scan cancer.
The treatment options include sentinel lymph node biopsy for patients with melanoma and surveillance imaging for those with squamous cell carcinoma of the skin.
Etan Marks, a pathologist and author of one of the studies, said they showed the Castle Biosciences tests provide physicians and patients insights that "enhance clinical decision-making and arm clinicians with more precise risk information to help route patients to the most appropriate modality aligned to their risk of metastasis and survival."
The company said the gene expression profiling and risk stratification tests show which patients are at lower risk and able to forgo certain tests.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.